Morgan Stanley
INDV icon

Morgan Stanley’s Indivior Pharmaceuticals INDV Stock Holding History

Morgan Stanley’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$139M Sell
3,395,702
-110,115
-3% -$3.99M 0.01% 1289
2026
Q1 		$107M Sell
3,505,817
-871,957
-20% -$28.8M 0.01% 1385
2025
Q4 		$157M Sell
4,377,774
-1,245,479
-22% -$38M 0.01% 1088
2025
Q3 		$136M Buy
5,623,253
+5,055,982
+891% +$106M 0.01% 1165
2025
Q2 		$8.36M Sell
567,271
-145,912
-20% -$1.7M ﹤0.01% 3600
2025
Q1 		$6.8M Sell
713,183
-2,830,909
-80% -$29.8M ﹤0.01% 3663
2024
Q4 		$44.1M Sell
3,544,092
-1,675,252
-32% -$17.2M ﹤0.01% 1943
2024
Q3 		$50.9M Buy
5,219,344
+5,075,758
+3,535% +$59.4M ﹤0.01% 1809
2024
Q2 		$2.31M Sell
143,586
-54,665
-28% -$987K ﹤0.01% 4466
2024
Q1 		$4.25M Buy
198,251
+192,338
+3,253% +$3.61M ﹤0.01% 4034
2023
Q4 		$90.3K Buy
5,913
+170
+3% +$3.02K ﹤0.01% 5981
2023
Q3 		$132K Buy
5,743
+3,899
+211% +$88.9K ﹤0.01% 5752
2023
Q2 		$43.9K Buy
+1,844
New +$42.3K ﹤0.01% 6259

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

Morgan Stanley's INDV Position: Q2 2026 in Review

Morgan Stanley reduced its Indivior Pharmaceuticals (INDV) stake by 3.1% in Q2 2026, selling an estimated $3.99M and leaving 3,395,702 shares worth $139M. The position accounts for 0.01% of the portfolio, ranked #1289.

Morgan Stanley first reported a position in INDV in Q2 2023 and has held it in 13 quarters since. The position peaked at $157M in Q4 2025. 338 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • Morgan Stanley held 3,395,702 shares of Indivior Pharmaceuticals worth $139M as of Q2 2026.
  • Morgan Stanley sold 110,115 Indivior Pharmaceuticals shares in Q2 2026, an estimated $3.99M.
  • Indivior Pharmaceuticals made up 0.01% of Morgan Stanley's portfolio in Q2 2026, its #1289 holding.
  • Morgan Stanley first reported a position in Indivior Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
  • Morgan Stanley's Indivior Pharmaceuticals position peaked at $157M in Q4 2025.
  • 338 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.